A pproximately 600 000 percutaneous coronary interventions (PCIs) are performed annually in the United States. 1 Periprocedural bleeding is a common complication of PCI, [2] [3] [4] [5] [6] occurring in 2% to 6% of cases. [6] [7] [8] [9] [10] [11] [12] Bleeding is associated with major adverse events, including short-and long-term mortality, 4, [8] [9] [10] [11] 13 as well as prolonged hospital length of stay (LOS) [7] [8] [9] [10] 14 and higher hospital costs. 6, 7, 15, 16 Periprocedural bleeding seems to be predictable and modifiable. 4 A validated risk prediction algorithm may help clinicians estimate bleeding risk in patients undergoing PCI, and established bleeding avoidance strategies (BAS), such as bivalirudin, radial artery access, and vascular closure devices, have been demonstrated to reduce bleeding. 2, [16] [17] [18] [19] [20] [21] [22] [23] [24] However, recent studies have reported that patients at highest risk for bleeding are least likely to receive treatment with BAS. 2, 5 Accurate preprocedure bleeding risk assessment scoring may provide a significant opportunity for physicians to selectively use effective preventative tactics in patients most likely to benefit and improve PCI safety, care quality, and subsequently hospitalization costs.
Goals and Vision of the Program
Bleeding events after cardiovascular procedures have been identified by the Centers for Medicare and Medicaid Services to be quality indicators among centers participating in its Acute Care Episode demonstration. 2 However, data on the impact of pre-PCI bleeding risk assessment on physician practice patterns, BAS use, and quality outcomes are sparse. We developed a quality improvement program for PCI patients using a preprocedure bleeding risk score to stimulate the use of consensus BAS in high-risk, high-cost patients. The specific aims of the program were to improve patient safety and care quality and to decrease LOS and hospital costs by reducing bleeding events and associated complications in PCI patients. An interdisciplinary team collaborated to design program elements directed at (1) using an automated real-time decision support tool to capture bleeding risk and provide critical information regarding consensus BAS recommendations in the catheterization laboratory immediately before PCI, (2) educating Emergency Department staff and physicians, interventional cardiologists, catheterization laboratory staff, and post-PCI care providers on the benefits of a pre-PCI decision support tool and the role of BAS in high bleeding risk cases, (3) providing feedback on performance measures and incidence of bleeding to providers to establish a continuous quality improvement mechanism, and (4) improving physician practice patterns and changing our healthcare system's bleeding complication profile over time. This report highlights key components of the protocol, the process of implementation, and initial clinical outcomes.
Local Challenges in Implementation
We first needed to identify a source from which valid, accurate data could be obtained. Second, we needed to provide robust education regarding the benefits of the pre-PCI decision support tool, as well as BAS in high-risk, high-cost patients to cardiac catheterization physicians, nurses, laboratory technicians, and hospital administrative leaders. We then constructed an easily applicable electronic tool for providers to access which included documentation in the electronic health record. Last, patient complications, LOS, and cost data were captured. diagnostic cardiac catheterization and PCI procedures and provides benchmark data to national averages and 90th percentiles.
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Provider Education
We took a deliberate and direct approach in educating Emergency Department staff and physicians, interventional cardiologists, catheterization laboratory staff, and post-PCI care providers across the Cardiovascular Service Line on the benefits of the pre-PCI decision support tool and the role of BAS in high bleeding risk PCI cases. This was executed through grand rounds presentations, multishift in-service training in all PCI-related areas including pharmacy, and making bleeding risk task group resources available to troubleshoot and problem-solve treatment strategy issues. The education program included regular site-specific outcomes feedback to interventional cardiologists and PCI centers.
Implementation of the Initiative
Real-Time Decision Support Tool
In May 2012, as part of a quality improvement program, the NCDR bleeding risk model 3 was incorporated into an automated decision support tool using Microsoft Excel software and made available to all catheterization laboratory computers across the 3 PCI centers ( Figure 1 ). The NCDR bleeding risk model assigns points Figure 1 . Pre-percutaneous coronary intervention (PCI) bleeding risk scoring tool-Image of the pre-PCI decision support tool integrated into the electronic health record. CHF indicates chronic heart failure; GFR, glomerular filtration rate; MI, myocardial infarction; and NYHA, New York Heart Association. to 9 preprocedural patient and clinical variables including acute coronary syndrome type, cardiogenic shock, sex, prior heart failure, prior PCI, New York Heart Association class IV heart failure, peripheral vascular disease, age, and estimated glomerular filtration rate to calculate individual bleeding risk scores. 3 By inputting patient demographic and clinical information into the application before PCI, bleeding risk scores are calculated and consensus BAS recommendations are displayed in real-time in the catheterization laboratory to interventional cardiologists and catheterization laboratory staff. Consensus BAS recommendations include one or more of the following in the absence of glycoprotein IIb/IIIa inhibitors: bivalirudin, radial artery access, and vascular closure device use.
PCI Dashboard
Patient clinical and outcomes data were obtained using a fully automated PCI dashboard. Data from all PCI patients discharged across the Cardiovascular Service Line on or after July 1, 2009, with records fully abstracted for the NCDR Cath-PCI Registry were included. Data obtained from NCDR data tables were linked to Allina Health's Enterprise Data Warehouse, a single shared electronic data repository that integrates data from Allina Health hospitals and clinics to support the comprehensive analysis needed to identify, measure, and improve clinical quality, financial outcomes, patient satisfaction, and regulatory compliance and reporting. Cost accounting and LOS data were obtained from comprehensive cost data within the Enterprise Data Warehouse. The PCI dashboard was used to measure the impact of provider education, as well as how the decision support tool influenced physician practice patterns, complication events, and quality outcomes.
Program Evaluation Study Design
This analysis was done as a quality assurance project, and institutional review board approval was not required. All PCI cases across the Cardiovascular Service Line entered into the NCDR CathPCI Registry were included. The study consisted of 2 stages: (1) validation and (2) 
Definitions
All data were based on NCDR definitions. 26 Any complication was defined as any intra-or postprocedure complication observed and documented in the medical record as occurring between the start of the PCI procedure until the next procedure or discharge.
RBC transfusion was defined as any transfusion(s) of either whole blood or packaged RBCs between the start of PCI until the next procedure or discharge. For this analysis, bleeding <72 hours was defined as any of the following events observed and documented in the medical record occurring within 72 hours after the PCI procedure and in the absence of active preprocedure bleeding: (1) any hemoglobin drop ≥3 g/dL; (2) any transfusion of whole or packaged RBCs within 72 hours of the procedure; (3) any procedural intervention or surgery at the bleeding site to reverse/stop or correct the bleeding. BAS included ≥1 of the following in the absence of glycoprotein IIb/IIIa inhibitor use: bivalirudin, radial artery access, and vascular closure device. 
Statistical Analysis
Descriptive statistics are displayed as medians and 25th and 75th percentiles for continuous variables; number and percentage with characteristic are given for categorical variables. Categorical variables were analyzed using Pearson χ 2 or Fisher exact tests. Continuous variables were analyzed using ANOVA for normally distributed variables or Kruskal-Wallis tests for continuous variables with non-normal distribution. A
Stage 2 Prospective Use Analysis: Success of the Initiative
Among 994 total high bleeding risk cases, 494 (49.7%) were in the stage 1 validation group and 500 (50.3%) were in the stage 2 prospective use group. The baseline patient demographics, risk factors, disease history, admission presentation, and BAS use for the stage 1 validation and stage 2 prospective use groups are presented in Table 2 . The only baseline difference was higher percentage of previous myocardial infarction and non-ST-segment elevation myocardial infarction presentation in the stage 2 prospective use group. There were significant increases in the use of any BAS, bivalirudin, radial artery access and vascular closure device use, and a significant decrease in glycoprotein IIb/IIIa inhibitor use in the stage 2 prospective use group (P<0.001 for all; Table 3 ). Among the 22 providers evaluated, 21 (95.5%) had greater BAS use during the stage 2 prospective period ( Figure 4) . The mean absolute increase for provider usage of BAS in high bleeding risk cases was 33.8% ± 16.7%. Complication events in the stage 1 validation and stage 2 prospective use groups are shown in Figure 5 . There was a significant decrease in complications 
Summary of the Experience, Future Directions, and Challenges
Using data from over 9500 PCI cases from 3 separate, highvolume PCI centers with a unified electronic medical record, we found that the NCDR bleeding risk model accurately distinguished patients at highest risk for complications, prolonged LOS, and increased hospital costs. Validating the NCDR risk algorithm using data from the Allina Cardiovascular Service Line provided the rationale and opportunity to use pre-PCI risk stratification to increase physician adherence to consensus BAS in high-risk, high-cost patients. Implementing a real-time decision support tool that incorporated the risk prediction model and provided consensus BAS recommendations in the catheterization laboratory immediately before PCI successfully changed physician practice patterns and reduced overall complication events in high bleeding risk patients. Periprocedural bleeding is a common and costly complication during PCI, a procedure performed ≈600 000 times in the United States annually. 1 Major bleeding has been reported to increase LOS by 2 to 6 days [7] [8] [9] [10] 14 and hospital costs by $5000 to $10 000. 6, 7, 15, 16 Bleeding is associated with several adverse outcomes, including ischemic events and stent thrombosis, 9 blood transfusions, 10 hospital readmissions for recurrent bleeding, 13 and in-hospital, 30-day and 1-year mortality. 4, [8] [9] [10] [11] 13 Thus, it is important to investigate strategies that will prevent PCI bleeding. 3 To our knowledge, only 1 previous study has used the NCDR bleeding risk model for pre-PCI risk stratification. Rao et al 27 found that individualized bleeding risk estimates increased bivalirudin use in intermediate and high bleeding risk patients and decreased bivalirudin use in low bleeding risk patients. These changes in bivalirudin use were associated with reductions in bleeding complications in intermediate and high bleeding risk patients without increasing bleeding in low bleeding risk patients. 27 The current study is distinct in several ways. First, we used a shared electronic medical record to review all PCI cases from 3 distinct, independent, high-volume centers. The consistency between bleeding events in our data with NCDR definitions for low (<1%), intermediate (1% to 3%), and high (>3%) bleeding risk indicates that uniform electronic medical records are accurate and practical resources for data collection in quality improvement initiatives. Second, validating the NCDR risk model's ability to accurately distinguish high-risk, high-cost cases provided the rationale for us to implement a quality improvement program with system-wide pre-PCI risk assessment scoring to selectively use BAS in patients most likely to benefit. Third, this study demonstrates the decision support tool's system-wide adoption. Within 1 month of implementation, the decision support tool was used to calculate pre-PCI bleeding risk scores for >75% of cases across each of the 3 sites ( Figure 6 ). This suggests that the application was effective, easy to use, and widely actionable in the catheterization laboratory among interventional cardiologists across 3 distinct, independent PCI centers. Fourth, our study demonstrates that pre-PCI risk assessment scoring effectively changed physician practice patterns in high bleeding risk cases. Bivalirudin and vascular closure device use significantly increased in high bleeding risk cases postprotocol implementation, while GPI IIb/IIIa use significantly decreased. Radial artery access significantly increased but remained low in the stage 2 prospective use group. In addition to increased BAS adherence in high bleeding risk cases, real-time decision support was associated with decreased BAS use in low bleeding risk cases (Figure 7) . Fifth, implementation of the decision support tool was associated with a decrease in overall complications, including reductions in RBC transfusions and bleeding events. These results may persuade clinicians, policymakers, and hospital administrators to adopt similar interventions to effectively guide strategies in PCI patients most likely to benefit and improve PCI safety and quality outcomes.
Although per patient LOS and total variable costs did not decrease in the stage 2 prospective use group, reducing overall complication events should result in lower annual LOS and hospital costs. In high bleeding risk cases, we observed a 2.1% absolute reduction in bleeding complications, a 3.5% absolute reduction in RBC transfusions, and a 5.3% absolute reduction in any complications postprotocol. In healthcare systems that perform a high volume of PCI procedures, achieving these improvements may lead to significant reductions in healthcare resource utilization, LOS, and hospital costs annually. Preventing hospital readmissions for recurrent bleeding would lead to further savings.
Conclusions
The NCDR bleeding risk model accurately identified highrisk, high-cost patients, providing the rationale and opportunity to use preprocedure risk stratification to guide the effective use of BAS in high bleeding risk patients undergoing PCI. Implementation of an easy-to-use, real-time decision support tool favorably changed physician practice patterns and significantly reduced complications. Decreasing complication events improves PCI quality and patient outcomes and may lead to reductions in LOS, readmissions, healthcare resource utilization, and hospital costs. 
